13F Holdings
中文EN

SCLX Scilex Holding Co

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1820190 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-28.5%
TTM net income YoY-473.7%
TTM EPS YoY-2,120.1%
Revenue 3-yr CAGR-12.0%
Net income 3-yr CAGR—

Margins

Gross margin161.1%
Operating margin-1,136.4%
Net margin-1,469.8%
FCF margin—
EBITDA margin-1,119.8%

Returns

ROE—
ROA-275.4%
ROIC (approx.)—
Asset turnover0.19x

Leverage & solvency

Liabilities / assets222.5%
Debt / equity—
Current ratio0.07x
Interest coverage-22.20x

Cash quality & payout

Operating cash flow / net income0.04x
Accruals ratio-265.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$30.25M$56.59M$46.74M$38.03M$31.32M
Cost of revenue$10.60M$16.69M$15.68M$10.80M$3.63M
Gross profit$125.80M$167.40M$31.06M$27.24M$27.68M
R&D expense$20.71M$9.64M$12.75M$9.05M$9.20M
SG&A expense$266.88M$119.02M$119.64M$64.89M$50.58M
Operating income-$346.01M-$83.40M-$105.43M-$50.63M-$35.84M
Interest expense$11.46M$1.96M$1.07M$9.60M$11.76M
Pretax income-$374.03M-$72.81M-$114.32M-$23.36M-$88.42M
Income tax$26,000-$1,000$13,000$4,000$5,000
Net income-$374.05M-$72.81M-$114.33M-$23.36M-$88.42M
EBITDA-$341.38M-$79.35M-$101.28M-$46.67M-$32.06M
EPS (basic)-36.48-7.24-1.28-0.17-0.67
EPS (diluted)-36.48-8.05-1.28-0.17-0.67
Weighted avg. shares (diluted)11,03410,145130.30M134.23M132.86M
Balance sheet
Cash & equivalents$4.96M$3.27M$4.73M$2.18M$4.34M
Short-term investments————$303,753
Receivables$15.24M$26.44M$34.60M$21.24M$14.27M
Inventory$4.79M$2.44M$4.21M$1.38M$2.56M
Current assets$38.36M$41.55M$46.78M$29.61M$23.00M
PP&E, net$13.60M$708,000$722,000$772,000$805,000
Goodwill$13.48M$13.48M$13.48M$13.48M$13.48M
Intangibles$59.09M$32.45M$36.48M$40.59M$38.80M
Total assets$364.98M$92.95M$101.31M$86.53M$77.93M
Current liabilities$483.65M$259.63M$250.38M$44.84M$169.42M
Short-term debt$83.26M$34.88M$108.43M$0$29.14M
Long-term debt———$0$72.04M
Total debt———$0$101.17M
Total liabilities$576.73M$285.59M$274.25M$50.29M$301.81M
Shareholders' equity-$207.78M-$192.64M-$172.94M$36.24M-$223.88M
Net debt———-$2.18M$96.83M
Shares outstanding7.03M5.24M100.02M141.35M132.86M
Cash flow statement
Operating cash flow$3.82M$19.35M-$20.71M-$21.26M-$28.66M
Capital expenditure$133,000$0$30,000$7,000$0
Free cash flow$3.68M$19.35M-$20.74M-$21.27M-$28.66M
Investing cash flow$4.08M-$2.67M-$330,000-$2.07M$0
Financing cash flow-$5.46M-$18.13M$23.58M$21.17M$28.16M
Depreciation & amortization$4.62M$4.05M$4.15M$3.96M$3.78M
Stock-based compensation$15.49M$15.69M$14.60M$5.28M$5.82M
Dividends paid—$8.65M$8.65M——

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.